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SUMMARY 
Background: Knowledge of independent, baseline risk factors of catheter-related thrombosis (CRT) may 
help select adult cancer patients at high risk to receive thromboprophylaxis. 
Objectives: We conducted a meta-analysis of individual patient-level data to identify these baseline risk 
factors. 
Patients/Methods: MEDLINE, EMBASE, CINAHL, CENTRAL, DARE, Grey literature databases were 
searched in all languages from 1995-2008.  
Prospective studies and randomized controlled trials (RCTs) were eligible. Studies were included if 
original patient-level data were provided by the investigators and if CRT was objectively confirmed with 
valid imaging.  
Multivariate logistic regression analysis of 17 prespecified baseline characteristics was conducted. 
Adjusted odds ratios (OR) and 95% confidence intervals (CI) were estimated.  
Results: A total sample of 5636 subjects from 5 RCTs and 7 prospective studies was included in the 
analysis. Among these subjects, 425 CRT events were observed. In multivariate logistic regression, the 
use of implanted ports as compared with peripherally implanted central venous catheters (PICC), 
decreased CRT risk (OR = 0.43; 95% CI, 0.23-0.80), whereas past history of deep vein thrombosis (DVT) 
(OR = 2.03; 95% CI, 1.05-3.92), subclavian venipuncture insertion technique (OR = 2.16; 95% CI, 1.07-
4.34), and improper catheter tip location (OR = 1.92; 95% CI, 1.22-3.02), increased CRT risk.  
Conclusions: CRT risk is increased with using PICC catheters, previous history of DVT, subclavian 
venipuncture insertion technique and improper positioning of the catheter tip. These factors may be useful 
for risk stratifying patients to select those for thromboprophylaxis.  Prospective studies are needed to 
validate these findings. 
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INTRODUCTION  
Indwelling central venous catheters (CVCs) are widely used to facilitate treatment in cancer 
patients. It is estimated that in the United States more than 5 million CVCs are inserted annually, with a 
significant proportion being used in cancer patients[1, 2]. These devices have revolutionized clinical 
practice and resulted in major improvements in the quality of care. Importantly, CVCs allow 
administration of intravenous therapy at home, thereby improving patients’ quality of life and reducing 
health care costs. However, these benefits come with a price. Many complications have been associated 
with the use of these devices, including catheter-related thrombosis (CRT), infection and other serious 
consequences[1, 3].  
The event rate of symptomatic CRT varies widely among studies, with earlier studies reporting 
risk as high as 28%, while more recent studies report a much lower risk, generally 5% or less[4-10]. It is 
estimated that symptomatic CRT represents only one third of all CRT events; the clinical significance of 
asymptomatic CRT remains uncertain[1]. CRT can delay the administration of chemotherapy, increase 
the risk of systemic infections, and lead to pulmonary embolism (PE)[11-15]. Treatment of CRT exposes 
patients to the hazards of anticoagulant therapy.   
Observational studies have attempted to elucidate risk factors of CRT. However, the data have 
often been limited by small sample sizes, and heterogeneity in their outcomes definitions as well as in the 
patient populations studied[16].  Furthermore, the use of prophylaxis is often unspecified and 
uncontrolled in these studies, leading to more uncertainty about the true incidence of CRT and the true 
benefits of anticoagulant prophylaxis. 
Although some early studies showed dramatic reductions in CRT with low dose warfarin or low 
molecular weight heparin (LMWH) [7, 17, 18], recent clinical trials [4, 5, 10, 19] did not show any 
benefit in terms of reducing symptomatic or asymptomatic events. Reasons for this discrepancy may 
include differences in catheter materials and design, outcome ascertainment and lack of statistical 
power[16]. 
  
 Identifying independent risk factors of CRT would provide a basis for individualized therapy.  
For example, anticoagulant prophylaxis could be limited to patients with a high risk of thrombosis, 
thereby sparing those with a low risk the potential harm associated with anticoagulation.  We performed a 
meta-analysis using individual patient-level data from prospective studies to identify clinical baseline risk 
factors that would be useful in risk stratifying patients for development of CRT. 
METHODS 
Data Sources and Searches 
We searched the following databases: MEDLINE, EMBASE, CINAHL (Cumulative Index to 
Nursing and Allied Health), Cochrane Central Register of Controlled Trials (CENTRAL), Database of 
Abstracts of Reviews of Effects (DARE), and the Grey literature databases (The New York Academy of 
Medicine-Grey Literature Report; MetaLib; Scientific meetings databases, which include American 
Society of Hematology and American Society of Clinical Oncology; and Google scholar). We also 
consulted experts in the field to identify additional studies.   
We used the following search terms: Central venous catheterization (text and MeSH) AND 
thrombosis, thromboembolism (text and MeSH) NOT haemodialysis, renal dialysis, hemodialysis, dialysis 
(text and MeSH) AND cohort studies clinical trials, longitudinal studies, prospective studies (text, MeSH, 
Publication type) AND 1995-2008. 
The MEDLINE electronic component of the search was updated on a daily basis between May 2007 and 
March 2008. 
 Study Selection 
The title and abstract were used to select for articles to be invited for participation. A study was 
eligible for the analysis if it met all the following inclusion criteria: (1) an observational prospective 
cohort study or randomized clinical trial; and (2) published between 1995 and March 1, 2008. Studies 
were excluded if they met any one of the following exclusion criteria: (1) conducted mainly in children < 
= 18 years of age; (2) dealt mainly with fibrin sheath formation, or intraluminal thrombosis of CVCs, and 
not with catheter-related deep vein thrombosis (DVT); (3) included mainly non-cancer patient populations 
  
(e.g. hemodialysis patients); (4) enrolled less than a total of 100 subjects; (5) did not use objective testing 
to confirm a diagnosis of CRT; (6) were duplicate publications containing data reported in later studies.  
Once the study selection was complete, authors of the publications were invited to collaborate and 
forward primary data for analysis.  A study was not included in the analysis if a response was not received 
after two reminders were sent to the investigator. 
 Data Extraction and Verification  
The investigators were asked to provide primary data on the following baseline variables on each 
subject: Age, sex, type of cancer, cancer stage, type of cancer therapy given, type of catheter, insertion 
side, insertion site, number of lumen, size of catheter, location of catheter tip, prophylactic 
anticoagulation use, number of attempts or a grade of difficulty of insertion, baseline platelet count, 
history of previous thrombosis, previous catheter insertion, and estrogen exposure in the form of oral 
contraceptive pills or hormone replacement therapy at the time of catheter insertion, and whether CRT 
developed or not. 
  We collected data from the publications on the following variables: duration of follow-up in each 
study, type of radiographic evaluation used to detect CRT in each study, and whether the study was 
designed to evaluate only symptomatic CRT vs. total CRT (symptomatic and asymptomatic). 
  One author (W.S.) evaluated the data from each study and compared the data with the publication 
for completion. Any discrepancy was resolved through discussion with the investigator.  
Quality Assessment 
Two authors (W.S. and T.M.) independently and in duplicate evaluated the methodological 
quality of the different studies using criteria described by Jadad et al. [20] for randomized clinical trials, 
and using the Newcastle-Ottawa Scale by Wells et al. [21] for nonrandomized prospective cohort studies. 
This quality assessment was not used to weigh the studies differently during the analyses.   
Data Synthesis and Analysis 
For subjects who received more than one catheter during the course of any of the studies [8, 22, 
23], only outcomes observed while they had their first device in place were evaluated in this project. If the 
  
study had data on cancer and non-cancer subjects[24], we only used the data reported on the cancer 
subjects.  
CRT was treated as a binary outcome. All the risk factors were treated as categorical and dummy 
variables were created for each category. A separate category was created for missing data for each 
variable, and a dummy variable was created for this category and was included in the regression analyses. 
This category [missing data category] was never chosen to be the referent group for any of the analyses.  
We conducted an unconditional multivariate logistic regression including all the prespecified 
baseline factors. We were unable to conduct a conditional logistic regression because some studies did not 
collect data on several variables that we adjusted for.  The risks for CRT were expressed as odds ratios 
(OR), with corresponding 95% confidence intervals (CI). 
For any risk factor that was significantly associated with CRT in the multivariate model, we 
assessed whether the association between this risk factor and CRT varied significantly between studies; 
this was accomplished by creating an interaction term between the risk factor and a variable that indicated 
study membership. Univariate logistic regression was employed for this analysis.  
We plotted a freedom from CRT survival curve for the entire sample using the Kaplan-Meier 
method. Survival data were lacking from several studies, so we were unable to account for potential 
competing risks.  
All statistical tests were two sided, and P values less than .05 were considered statistically 
significant. All analyses were conducted using SAS version 9.1. 
 IRB Approval  
This project was submitted to the University of Wisconsin Institutional Review Board and was 
exempted from full review. The contributing co-authors obtained approval from their local IRBs in 
accordance with their local guidelines.   
  
Results 
Studies that were identified 
Our search identified two hundred and forty one references in MEDLINE, eight references in 
EMBASE, and ten abstracts. Forty four references (40 papers and 4 abstracts) met our eligibility criteria 
(Figure 1). Twenty-two investigators in 7 countries agreed to participate. We were not able to use data 
from 5 of the studies because of various technical difficulties (missing data code for 2 studies; obsolete 
software for 3 studies). We received the data for one study[25] after closure of the database and 
completion of the analysis; therefore, results from this study were not included in the current analysis. 
Three reports were based on the same participants; data from one of these three reports were used.  Data 
for 2 studies could not be retrieved. Hence, the current results represent the pooled data from 12 studies 
[4, 8-10, 19, 22-24, 26-29].  
 Baseline characteristics of the Studies and Patient Sample 
Table 1s (online only) summarizes some of the key features of the 12 studies. Five were 
randomized clinical trials and seven were prospective cohort studies. Nine studies included subjects with 
solid as well as hematologic malignancies; whereas in three studies only subjects with either solid or 
hematologic malignancies were included. Only five studies included all three types of central venous 
catheters. The primary outcome in 8 studies was clinically overt, symptomatic CRT. In most studies no 
routine screening for thrombosis was performed. Median duration of follow up among 11 studies ranged 
between 15 days and 237 days; one study reported a maximum duration of follow up of 530 days. 
Ultrasonography and venography were the diagnostic modalities most frequently used to confirm a 
diagnosis of CRT. The sample sizes ranged between 100 and 1533 subjects. 
Table 1 summarizes the main characteristics of the patient sample used for the analysis. By 
pooling all 12 studies, a total of 5636 subjects with 425 CRT events were observed. The median age was 
59 years (interquartile range [IQR] 50-67). There were roughly equal proportions of men and women. The 
most frequent type of catheter used was the chest wall external central venous catheter (including 
tunneled and non-tunneled), followed by implanted ports; PICC catheters were the least frequent type 
  
used (15%). Most (60%) subjects did not have a history of deep vein thrombosis. Single lumen catheters 
were placed in 76% of patients and 55% of the insertions placed the catheter tip at the junction between 
superior vena cava and right atrium. The majority (80%) of patients had solid tumors, 60% had advanced 
disease and 75% were receiving chemotherapy.  The proportion of the subjects who received any form of 
thromboprophylaxis was roughly equal to the proportion who did not receive any form of 
thromboprophylaxis, at 45%. Data were not available in 50% or more of patients for the following 
variables: site of insertion; difficulty of the insertion procedure; history of catheter placement; baseline 
platelet count; and use of estrogen products. The main reason for missing data was that not all of the 
studies collected data on all of the seventeen variables that were examined in this analysis. 
Assessment of the Quality of Studies 
Table 2s (online only) summarizes the independent assessment of the quality of the 12 studies. 
Overall, the quality of the randomized clinical trials ranged from very good to excellent with no study 
having a JADAD score of less than 3.  
  For the cohort studies, two studies had relatively short follow-up duration [23, 24] and one study 
did not report on the adequacy of follow-up [28]. Otherwise, all the studies met the assessment criteria for 
non-randomized cohort design.  
Results of the Multivariate Logistic Regression Analysis 
Table 2 summarizes the results of the multivariate logistic regression analysis. All 17 prespecified 
risk factors were included in the multivariate model.  The following variables were significantly 
associated with a higher CRT risk: (1) Subclavian vein insertions compared to upper arm veins insertions 
(OR 2.16; 95% CI 1.07-4.34); (2) previous history of deep vein thrombosis (OR 2.03; 95% CI 1.05-3.92); 
(3) catheter tip positioned more proximal than the junction between SVC and RA (OR 1.92; 95% CI 1.22-
3.02). Only one variable was significantly associated with lower CRT risk: implanted ports when 
compared to PICC catheters were associated with a roughly 60% relative risk reduction (RRR) (OR 0.43; 
95% CI 0.23-0.80). Chest wall external CVCs were also associated with 40% RRR as compared with 
PICC catheters, but this failed to reach statistical significance  (OR 0.60; 95% CI 0.33-1.10).  
  
A number of risk factors were associated with a higher risk of CRT, but none reached statistical 
significance. These include: (1) higher lumen number; (2) technically difficult procedures; (3) lack of 
thromboprophylaxis; (4) estrogen exposure; and (5) left sided insertions; see also Table 3s (online only). 
 Heterogeneity Assessment 
Table 4s (online only) summarizes the results of the analysis of heterogeneity of the associations 
between catheter type, proper catheter positioning, prior history of deep vein thrombosis, site of insertion, 
and CRT. The only association that varied significantly between studies was the association between 
proper catheter positioning and risk of CRT.  
Kaplan-Meier Survival Analysis of CRT 
Figure 2 displays the freedom from CRT survival curve based on the Kaplan-Meier method. The 
median duration of follow up of CRT-free subjects was 133 days (interquartile range (IQR), 51-248 
days). Most events occurred during the first 100 days of follow up. The cumulative incidence of CRT is 
8.5% at 6 months, 10% at 1 year, and 12% at 2 years. The median number of days between catheter 
insertion and CRT was 15 days (IQR, 8-47). 
Discussion and Conclusions 
This study is the first individual patient-level data meta-analysis designed to identify baseline 
patient- and catheter-related risk factors of CRT in patients with cancer.  Based on prospectively collected 
data on 5636 patients with 425 CRT events in 12 studies conducted between 1995 and 2008, we found 
that a history of deep vein thrombosis, subclavian venipuncture site, and improper catheter tip location 
increased the risk of CRT.  Furthermore, the risk of CRT was higher in patients with PICC catheters than 
in those with implanted port devices.  
Because CRT is an important complication of indwelling central venous catheters, prophylaxis 
with anticoagulants has been recommended previously.  However, contemporary randomized controlled 
trials evaluating warfarin and low molecular weight heparin prophylaxis have failed to show a reduction 
in symptomatic events [4, 5, 10, 19]. Furthermore, given that the rate of symptomatic CRT is low at 
5%[1], the most recent American College of Chest Physicians Consensus Guidelines in 2008 advised 
  
against the routine use of anticoagulant prophylaxis to prevent CRT[30, 31].  It seems likely, however, 
that selecting patients at higher risk of CRT to receive prophylaxis would be beneficial and useful.  
Unfortunately, previous studies have lacked the power to identify risk factors with certainty because of 
low event rates and small sample sizes, among other limitations. Individual patient-level data meta-
analysis offers an opportunity to enhance statistical power using information that is already available.  
This is particularly efficient for studying uncommon events.  
  Our findings confirm those in previous studies.  A history of venous thrombosis has been reported 
to predict for future episodes of thrombosis; this may indicate the patient is predisposed because of 
familial or acquired thrombophilia [1, 16, 24].  Subclavian venipuncture site has been associated with a 
higher risk of CRT in a number of papers [16]. This may be due to anatomical or technical factors.  
Improper position of the catheter tip has also been associated with increased risk of CRT [1, 16]. Having 
the tip at the junction of the SVC and right atrium may be protective because of a greater dilutional effect 
when vasculotoxic agents are infused, or because there is a lower likelihood that the tip of the catheter 
will be in direct contact with the endothelium.  Finally, implanted port devices may be associated with a 
lower risk of CRT than PICC because of a lower incidence of infection (which in turn can lead to 
thrombosis), or because the shorter catheter track with port devices reduces endothelial trauma.  A 
retrospective study in patients with hematologic malignancies demonstrated in multivariate analysis that 
CRT risk was higher with the use of PICC catheters as compared with centrally inserted catheters[32]. 
Whether bedside insertion of PICC, a frequent practice at most centers, leads to more complications than 
insertion of devices under radiologic imaging guidance has not been established. The potential 
mechanisms proposed here warrant study and validation. 
Our project has several strengths. Our search strategy was comprehensive. Our sample is large 
and widely representative and increases the external validity of our results. We excluded studies 
published prior to 1995 because changes in catheter design, material, insertion techniques, post-insertion 
catheter care, and diagnostic imaging accuracy would likely introduce significant heterogeneity and the 
results would not be relevant for contemporary practice. We excluded studies with fewer than 100 
  
patients due to the limited number of CRT events in each study. We included asymptomatic cases if they 
were objectively confirmed because the risk factors are likely the same for symptomatic and 
asymptomatic events. Given that we only had 4 studies that included symptomatic and asymptomatic 
events, a sensitivity analysis that is restricted to this group would have been extremely limited with regard 
to its sample size and power; therefore, this analysis was not conducted.  
Our data should be interpreted in the context of the following limitations. First, several variables 
had large amount of missing data. Second, the low 1-year and 2-year event rates limited our ability to 
assess heterogeneity. Third, although we adjusted for many confounders, there are other potential 
confounders that were not controlled for due to lack of data; for e.g., we did not have data on the use of 
certain well known prothrombotic antineoplastic agents (e.g., lenalidomide and thalidomide [33]), nor did 
we have detailed data on the schedule of chemotherapy (e.g. infusion or blous) or the type of 
chemotherapy that was used (e.g. sclerosing vs. nonsclerosing); the latter property was shown to be an 
important predictor of CRT[7]. Similarly, we were unable to adjust for exact type of cancer (only whether 
it was solid or hematologic), or the presence of familial thrombophilia (it has been reported that factor V 
Leiden and prothrombin G20210A mutation status are significant predictors of CRT[24, 34, 35]). Fourth, 
variable duration of follow up and inconsistent reporting of survival data limited our ability to account for 
competing events and may have limited our ability to accurately estimate the true incidence of CRT over 
time. Fifth, inability to obtain primary data from all studies that met our eligibility criteria. Due to the 
limitations listed above, our findings should be viewed as exploratory and require validation.  
In conclusion, we identified four independent risk factors of CRT using individual patient level 
data from prospective studies.  Validation of the results could lead to the development of risk 
stratification models that will help to tailor prophylaxis therapy in cancer patients with indwelling central 
venous catheters. 
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Table 1.  Baseline characteristics of all participants and according to their CRT status. 
Variable All Participants According to CRT status 
  No CRT With CRT 
Age, yr    
        Median (IQR) 59 (50-67)   
Age, yr – no. (%)*    
        < 60 yr  2877 (51) 2641 (51) 236 (56) 
        ≥ 60 yr 2757 (49) 2568 (49) 189 (44) 
       Missing 2                   2                  0 
Sex – no. (%)*    
       Male 2881 (51) 2675 (51) 206 (48) 
       Female 2747 (49) 2528 (49) 219 (52) 
       Missing 8         8 (0.15) 0 
Type of Catheter – no. (%)*     
       PICC  875 (15)   836 (16)  39 ( 9) 
       CVC† 2523 (45) 2304 (44) 219 (52) 
       Implanted Ports 1904 (34) 1788 (34) 116 (27) 
      Missing 334 ( 6)  283 ( 5)   51 (12) 
Insertion Site – no. (%)*    
      Upper arm Veins   808 (14)   772 (15)   36 (  8) 
      Subclavian Vein 1447 (26) 1210 (23) 237 (56) 
       Internal Jugular Vein   413 (  7)              389 (  7)                              24 (  6) 
       Others      22 (0.4)                 22 (0.4)                  0 (  0) 
       Missing 2946 (52)             2818 (54) 128 (30) 
Past Medical History of DVT    
       Present 131 ( 2)               117 ( 2)  14 ( 3) 
       Absent         3387 (60)  3096 (59) 291 (68)  
       Missing         2118 (38)              1998 (38)              120 (28) 
Catheter Size – no (%)*    
       < 6.5 French         1946 (35)             1849 (35)  97 (23) 
       ≥ 6.5 French         1871 (33)             1625 (31)              246 (58) 
          Missing 1819 (32) 1737 (33) 82 (19) 
Lumen Number – no. (%)*    
       Triple             33 (0.59)                 31 (0.6)                  2 (0.5) 
       Double           570 (10)               531 (10)                39 ( 9) 
       Single         4310 (76) 4028 (77)               282 (66)  
       Missing   723 (13)    621 (12)               102 (24)  
  
Table 1. Continued. 
 
Variable All Participants According to CRT status 
  No CRT With CRT 
Grading of technical difficulties 
during Catherer insertion – no. (%)* 
   
     Easy         1300 (23)  1256 (24)          44 (10) 
     Difficult           213 (  4)              203 (  4)          10 (  2) 
     Missing         4123 (73) 3752 (72)        371 (87)  
Past History of Catheter Insertion – 
no. (%)* 
   
     Present           171 (  3)   149 (  3) 22 (  5) 
     Absent         1716 (30)           1466 (28)         250 (59) 
     Missing         3749 (67)            3596 (69)        153 (36) 
Baseline Platelet Count – no (%)*    
     < 100 K/uL           219 (  4)   212 (  4)  7 (  2) 
     100-499 L/uL         1863 (33)           1642 (32)         221 (52)  
     ≥ 500 K/uL             99 (  2)               91 (  2)            8 (  2) 
     Missing         3455 (61)            3266 (63)         189 (44) 
Catheter Tip Location at the  
Junction between SVC and RA or in 
RA – no. (%)* 
   
      Yes         3082 (55)           2846 (55)        236 (56) 
      No 547 (10)             511 (10)          36 (  8) 
      Missing         2007 (36)           1854 (36)         153 (36) 
Any form of Thromboprophylaxis  
given – no. (%)‡ 
   
      Yes         2545 (45) 2337 (45)        208 (49)  
      No         2460 (44) 2270 (44)        190 (45)  
      Missing           631 (11)   604 (12) 27 (  6) 
Current or Recent Exposure to 
Estrogen (OCP or HRT) – no. (%)* 
   
     Yes 30 (  1)               22 (0.4)  8 (  2) 
     No           410 (  7)             360 (  7) 50 (12) 
     Missing         5196 (92)            4829 (93)        367 (86) 
  
Table 1. Continued. 
 
Variable All Participants According to CRT status 
  No CRT With CRT 
Cancer Stage – no. (%)    
    Early 1381(24.5)  1257 (24) 124 (29) 
    Advanced         3448 (61)            3214 (62) 234 (55) 
    Missing           807 (14)    740 (14)   67 (16) 
Anticancer Therapy – no. (%)*    
    Only Chemotherapy         3981 (71)            3663 (70)         318  (75) 
    Combined Chemoradiotherapy           234 (  4)              222 (  4)           12  (  3) 
    Only Radiotherapy             80 (  1)                79 (  2)             1  (0.2) 
    No therapy           718 (13)              693 (13)           25  (  6) 
    Missing           623 (11)              554 (11)           69  (16) 
Disease Type – no. (%)*    
    Hematologic Cancers           937 (17)    864 (17)   73 (17) 
    Solid Cancers         4561 (81)  4218 (81) 343 (81) 
    Others  37 (0.6)      35 (  1)      2 (0.4) 
    Missing           101 (  2)      94 (  2)     7 (  2) 
Side of Catheter Insertion –  
no. (%)* 
   
    Right         2272 (40)  2030 (39) 242 (57) 
    Left         1097 (19)    981 (19) 116 (27) 
    Missing         2267 (40)  2200 (42)   67 (16) 
    
Total – no (%)*         5636 (100)       5211 (92.46)    425 (7.54) 
Abbreviations: CRT, catheter-related thrombosis; IQR, interquartile range; PICC, peripherally implanted central catheter; CVC, 
central venous catheter; DVT, deep vein thrombosis; SVC, superior vena cava; RA, right atrium; OCP, oral contraceptive pills; 
HRT, hormone replacement therapy. 
* The sum of the percentages may not equal 100 percent due to rounding errors. 
†Include Hickman catheters and non-tunneled catheters. 
‡Include Antiplatelet agents; prophylactic doses of unfractionated heparin and low molecular weight heparin, minidose   
warfarin (1 mg daily) and dose adjusted warfarin (target International Normalized Ratio (INR), 1.5-2).  
  
Table 2.  Adjusted Odds Ratios of Risk Factors of CRT.* 
Variable             Multivariate Analysis 
                       Odds Ratio                                              P Value 
                          (95% CI) 
Type of Catheter  
    PICC 
    Chest wall external CVC 
    Implanted Port 
Insertion Site 
    Upper arm Veins 
    Subclavian Veins 
    Internal Jugular Vein 
Past Medical History of DVT 
    Absent 
    Present 
Catheter Tip Location at the 
Junction between SVC and RA, 
or in RA 
    Yes 
    No 
Lumen Number 
    Single 
    Double 
    Triple 
Grading of technical difficulties 
during Catheter insertion 
    Easy 
    Difficult 
Any form of 
Thromboprophylaxis given‡ 
    No 
    Yes 
Current or Recent Exposure to 
Estrogen (OCP or HRT) 
    No 
    Yes 
Side of Catheter Insertion  
    Right 
    Left 
 
 
 
1 [Reference]† 
0.60 (0.33-1.10) 
0.43 (0.23-0.80) 
 
1 [Reference]† 
2.16 (1.07-4.34) 
1.56 (0.71-3.40) 
 
1 [Reference]† 
2.03 (1.05-3.92) 
 
 
 
1 [Reference]† 
1.92 (1.22-3.02) 
 
1 [Reference]† 
1.34 (0.87-2.04) 
  3.79 (0.75-19.21) 
 
 
1 [Reference]† 
1.78 (0.79-4.00) 
 
 
1 [Reference]† 
0.80 (0.63-1.03) 
 
 
1 [Reference]† 
1.65 (0.64-4.23) 
 
1 [Reference]† 
1.28 (0.97-1.70) 
 
 
 
.10 
  .008 
 
 
 .029 
          .26 
 
 
 .034 
 
 
 
 
 .004 
 
 
.17 
.10 
 
 
 
.16 
 
 
 
.09 
 
 
 
.29 
 
 
  .079 
Abbreviations: CRT, catheter-related thrombosis; CI, confidence interval; CVC, central venous catheter; PICC, peripherally 
implanted central catheter; DVT, deep vein thrombosis; SVC, superior vena cava; RA, right atrium; OCP, oral contraceptive 
pills; HRT, hormone replacement therapy. 
*Odds ratios and 95% CI are not shown for Missing data category.  
†Reference group for the logistic regression analysis.  
‡Include antiplatelets; prophylactic dosages of heparin (unfractionated and low molecular weight heparin); minidose warfarin  
   (1mg daily) and dose adjusted warfarin (target International Normalized Ratio, 1.5-2). 
  
 
  
 
